Hepatitis B immune globulin to prevent hepatitis B recurrence after liver transplant: A single-center experience

Table 1 Hepatitis B surface antigen positive patient characteristics and post-liver transplant hepatitis B immune globulin treatment outcomes

Patient characteristics					Serologies at 2 months post-LT			Serologies at 6 months post-LT			Serologies at 12 months post-LT
Age, sex	Reason for LT, co-infection	HBV DNA pre-LT (IU/mL)	HBIG therapy duration (months)	NA post-LT	HBsAg	HBV DNA (IU/mL)	HBsAb titer (mIU/mL)	HBsAg	HBV DNA (IU/mL)	HBsAb titer (mIU/mL)	HBsAg	HBV DNA (IU/mL)	HBsAb titer (mIU/mL)
55, male	Cirrhosis	< 10	Did not receive	TAF	Negative	0	-	Negative	0	-	Negative	0	-
59, male	Cirrhosis, HCC	0	Did not receive	TDF	-	0	-	-	-	-	Negative	0	3
49, male	Cirrhosis, HCC	< 10	Did not receive	TAF	-	0	-	-	0	-	-	0	-
50, male	Cirrhosis, HCC	< 10	Did not receive	TDF	-	0	-	-	-	-	-	0	-
59, female	Acute liver failure	71000000	4	TDF	Negative	10	-	-	-	-	Negative	-	-
58, female	Cirrhosis	0	6	TAF	Negative	0	-	Negative	0	242	Negative	0	19
64, male	Cirrhosis, HIV	1000000000	6	TAF	-	84	-	-	10	-	-	10	-
67, male	Cirrhosis	141	6	TDF	Negative	10	-	Negative	10	-	Negative	10	-
59, male	Cirrhosis	128	6	TDF, entecavir	Negative	20	294	-	0	-	-	-	-
59, male	Cirrhosis, HCC, HDV	0	6	TDF	Negative	0	-	Negative	0	1000	Negative	0	759
46, female	Acute liver failure	7110	6	TAF, TDF, Entecavir	-	19	-	-	0	-	Negative	10	3
60, female	Cirrhosis	214000000	12	Entecavir	Negative	77	14	Negative	18	24	Negative	10	104
48, female	Acute liver failure	1010	6	TAF	Negative	0	-	-	0	-	Negative	0	5
56, male	Cirrhosis, HCC	< 10	5 days (intra-/post-operatively	TAF	Negative	0	791	-	-	-	Negative	0	3

HBsAb: Hepatitis B surface antibody; HBsAg: Hepatitis B surface antigen; HBIG: Hepatitis B immune globulin; HDV: Hepatitis D virus; HCC: Hepatocellular carcinoma; LT: Liver transplant; NA: Nucleos(t)ide analogue; TAF: Tenofovir alafenamide; TDF: Tenofovir disoproxil fumarate.